BridgeMD
New treatment option for Pancreatic Cancer
Official title Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
ClinicalTrials.gov ID: NCT02361320
What this study is testing
- What it's testing
- This trial studies how well computed tomography works in diagnosing patients with pancreatic or hepatobiliary cancer. Computed tomography may help researchers predict how patients with pancreatic or hepatobiliary cancer may respond to chemotherapy.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- PANCREATIC CANCER: Histologically confirmed adenocarcinoma of the pancreas
- PANCREATIC CANCER: Non-distant metastatic pancreatic cancer that is either
- Unresectable locally advanced disease, defined as primary tumor that involves \> 180 degrees of the superior mesenteric artery, celiac axis or any of...
- Borderline resectable disease, defined as primary tumor that involves =\ = 50% of the vessel circumference) a short segment of the common hepatic...
- PANCREATIC CANCER: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
You likely can't join if
- Presence of distant metastasis
- Patients whose tumors are defined as resectable
- Unstable angina or New York Heart Association grade II or greater congestive heart failure
- Evidence of fever or acute infection (chronic infection such as hepatitis virus is acceptable)
- Coexisting medical condition that would preclude chemotherapy, radiotherapy, or iodine-based contrast enhanced CT scan
- Pregnant women with a positive pregnancy test
See the full eligibility criteria
- PANCREATIC CANCER: Histologically confirmed adenocarcinoma of the pancreas
- PANCREATIC CANCER: Non-distant metastatic pancreatic cancer that is either
- Unresectable locally advanced disease, defined as primary tumor that involves \> 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that occludes the superior...
- Borderline resectable disease, defined as primary tumor that involves =\ = 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin)
- PANCREATIC CANCER: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
- PANCREATIC CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception and...
- PANCREATIC CANCER: Patient who has been recommended chemotherapy treatment for pancreatic cancer
- PANCREATIC CANCER: Signed study-specific consent form
- HEPATOBILIARY CANCER: Diagnosis of
- Hepatocellular carcinoma: This may be diagnosed in the following ways:
- Pathologically (histologically or cytologically) proven diagnosis of hepatocellular carcinoma (HCC)
- At least one solid liver lesion with arterial enhancement and washout on a delayed phase of a multi-phasic CT or MRI in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis
- Intrahepatic cholangiocarcinoma: Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma
- HEPATOBILIARY CANCER: Patients may have single or multinodular tumors
- HEPATOBILIARY CANCER: ECOG PS 0-1
- HEPATOBILIARY CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception
- HEPATOBILIARY CANCER: Prior history of surgical resection, chemotherapy, transarterial chemoembolization (TACE), and/or radiofrequency ablation are allowed
- HEPATOBILIARY CANCER: Patients may be enrolled if:
- The patient is dispositioned to receive definitive radiotherapy
- The patient has received definitive radiotherapy within the past two years and has liver protocol CT or MRI scans before radiotherapy and at first restaging after radiotherapy
- HEPATOBILIARY CANCER: Signed study-specific consent form
- Presence of distant metastasis
- Patients whose tumors are defined as resectable
- Unstable angina or New York Heart Association grade II or greater congestive heart failure
- Evidence of fever or acute infection (chronic infection such as hepatitis virus is acceptable)
- Coexisting medical condition that would preclude chemotherapy, radiotherapy, or iodine-based contrast enhanced CT scan
- Pregnant women with a positive pregnancy test
- Inability to comply with study and/or follow-up procedures
- Patients with an active second malignancy with the exception of non-melanoma skin cancer
The study team makes the final eligibility decision.
Where it's taking place
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.